Agoracom Blog Home

Posts Tagged ‘MOTA’

Mota Ventures $MOTA.ca Signs Letter of Intent to Acquire German Leader in Psilocybin Space with a 110,000 Square Foot Manufacturing Facility $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 7:49 AM on Thursday, May 14th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / ACCESSWIRE / May 14, 2020 /Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company“) announces that it has entered into a letter of intent (the “Letter of Intent“), dated May 11, 2020, with Verrian Ontario Ltd. (“Verrian“), pursuant to which the parties intend to evaluate a potential transaction involving the acquisition of all of the outstanding share capital of Verrian (the “Proposed Transaction“). Verrian is an arms’-length privately-held company that is focused on delivering and developing products related to addiction reduction, with a focus on alcohol and opiates.

ESTABLISHED EUROPEAN PSYCHEDELIC MEDICINE COMPANY

Verrian owns and operates an EU-GMP, ISO 14001 compliant 110,000 sq. ft. pharmaceutical manufacturing facility in Radebuel, Germany. Verrian purchased the facility from a major global pharmaceutical manufacturer in 2019. Both the facility and equipment are independently appraised at Cdn$10,600,000, including an analytical laboratory, and full pharmaceutical manufacturing suite.

Operations within this full suite pharmaceutical manufacturing site include analytical laboratory and finished dose manufacturing, which exceed all international quality standards.

Verrian is composed of three distinct business segments:

  • Pharmaceutical Manufacturing – A portfolio of medical & wellness products
  • Phyto API – API creation from medical plants
  • Analytical Testing – European Medicine Agency Standards

PRODUCTS FOCUSED ON OPIATE ADDICTION REDUCTION

Verrian’s singular focus is rewiring the mind to overcome addiction through natural medicine. Specifically, the micro dosing of psilocybin demonstrates potential to remove the dopamine reward of addictive substances, potentially diminishing the desire for addictive substances, thereby reducing or eliminating the need for the addictive substance.

To date Verrian has developed:

  • PSI GEN and
  • PSI GEN+

These Psilocybin products are focused on opiate addiction reduction. As Natural Psilocybin extracts, from organically cultivated mushrooms, combined with metabolism enhancing natural herbs, they are ideal for individuals commencing micro-dosing and capable of being combined with additional anti-addiction therapies.

All of Verrian’s compounds are derived from organic, glyphosate free naturally occurring plants, grown specifically for its own purposes.

GOALS AND VISION

In addition to facility & equipment investments outlined above, the company has invested Cdn$2,400,000 worth of clinical trial design development and proprietary formulations into its psilocybin trademarked PSI-GEN formulations, and cannabis products, including trademarked CBDaily and CBNight.

Verrian’s world renowned addiction medicine experts are moving ahead to develop new potential treatments for therapy, with rigorous clinical research. Once EU GMP & narcotics handling recertification are secured, capabilities will extend to:

  • Specialty Pharma – Custom formulations
  • Psilocybin Refinement & Production – For micro dosing

“I am extremely excited at the opportunity to acquire an established Psychedelic medicine company in Europe. As an innovative company, Mota always seeks to be a leader in the natural health space and we see the psychedelic medicine market becoming a major part of the industry. This acquisition allows us to have first mover advantage in the Psychedelic market, and Mota’s existing distribution network will be ready to capitalize on the opportunity once regulation has been put in place,” stated Ryan Hoggan, CEO of the Company.

The Letter of Intent contemplates that the Company would acquire all of the outstanding share capital of Verrian in consideration for Cdn$21,100,000, of which Cdn$20,000,000 will be satisfied through the issuance of common shares (the “Consideration Shares“) to the existing shareholders of Verrian, and the balance will be payable in cash to retire certain outstanding shareholder loans due and owing by Verrian. The Consideration Shares will be subject to the terms of a thirty-six month time release pooling arrangement, during which time they may not be transferred, assigned, pledged or otherwise traded.

Readers are cautioned that the Letter of Intent entered into with Verrian does not set forth the final terms of the Proposed Transaction, nor have such terms been finalized. Any consideration offered to acquire Verrian remains subject to the results of ongoing due diligence. Completion of the Proposed Transaction is subject to a number of conditions, including, not limited to, completion of due diligence, negotiation of definitive documentation, and the receipt of any required regulatory approvals. The Proposed Transaction cannot be completed until these conditions are satisfied and there can be no assurance that the Proposed Transaction will be completed at all.

The Proposed Transaction is not expected to constitute a fundamental change for the Company, nor is it expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. The Company will provide further information regarding its review of Verrian, and the Proposed Transaction, as that information becomes available.

About Mota Ventures Corp.

Mota Ventures is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Mota Ventures $MOTA.ca Reports Record Revenues for Month of April of CDN$3,818,000 From CBD Products, an Increase of 39% From April 2019 $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 7:37 AM on Monday, May 11th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / ACCESSWIRE / May 11, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company“) subsidiary, Nature’s Exclusive, an ecommerce provider of CBD products to consumers in the United States and Europe, is pleased to announce record revenues for the month of April totaling Cdn$3,818,000, representing an increase of 39% compared to April 2019. Expenses totaled Cdn$3,609,000, representing a Gross Profit of Cdn$209,000 for the month.

DOMINANT ONLINE CUSTOMER ACQUISITION STRATEGY

The Company credits this success to its’ online customer acquisition strategy, which is capitalizing on the strong consumer demand for natural health solutions, resulting in an interim record number of customer acquisitions for the Nature’s Exclusive brand, as well as, new customers for the immune support category introduced in March 2020.

The Company’s strong ability to continue capturing customers, for both existing and new products, bodes well for the Company’s CBD based hand sanitizer launch this month.

Ryan Hoggan, CEO of the Company stated, “I am very pleased to report another successful month with increased sales over 2019. Our investment in customer acquisition in March 2020, which yielded additional subscribers, has been a significant driver to our increased profitability. Despite the worldwide pandemic, we continue to move forward towards our full year goals for 2020, including expansion into the European market. I look forward to reporting on new customer acquisitions in the coming weeks”.

NATURE’S EXCLUSIVE CBD BRAND LEADING THE WAY

The Company’s Nature’s Exclusive brand offers a CBD hemp-oil formulation intended to provide users with the therapeutic benefits that hemp may offer. The hemp oil used in the products is derived from hemp grown and cultivated in the United States. The extraction process is designed to maintain all the beneficial qualities that hemp may offer. Nature’s Exclusive offers a range of products, which include CBD oil drops, CBD gummies, CBD pain relief cream, CBD skin serum, CBD hand sanitizer and CBD coffee.

We encourage readers to visit www.motaventuresco.com to view our brands and sign up to our newsletter.

We encourage shareholders and prospective investors to visit the Company’s AGORACOM Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

The Company cautions that figures for revenue, expenses and margin generated from the sale of Nature’s Exclusive products have not been audited, and are based on calculations prepared by management. Actual results may differ from those reported in this release once these figures have been audited. These figures were translated from US dollars into Canadian dollars using the Bank of Canada monthly average exchange rate of US$1.00:Cdn$1.4058 for April 2020 and US$1.00:Cdn$1.3378 for April 2019.

About Mota Ventures Corp.

Mota is an established ecommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan

Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Hemp Groups Pool Resources To Ensure Path to CBD Market in Europe SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 11:30 AM on Friday, May 8th, 2020

PONSOR: Mota is seeking to become a vertically integrated global CBD brand. Mota is creating sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota. Combined total sales of almost $29,000,000 with a EBITDA of approximately 12.5% (2019) Click Here for More Info

Mota large

With time ticking down for CBD manufacturers to meet the UK’s deadline for having a validated EU novel food application in hand, two European hemp associations are pooling resources to meet the application’s requirements.

The assistance on offer from the European Industrial Hemp Association in Germany and the Association for the Cannabinoid Industry in the UK highlights the urgency with which suppliers and processors need to move if they hope to be selling cannabidiol supplements and foodstuffs on the British market early next year.

That’s because the UK’s Food Standards Agency (FSA) set a deadline of March 31, 2021, for industry players to gather data on their CBD products and have their novel food applications validated by EU authorities.

The legality of CBD products in the European Union became murky in January 2019, when EU authorities classified all hemp extracts and hemp-derived products containing CBD and other cannabinoids as “novel foods.”

The designation means that manufacturers need to have their CBD supplements and edible products evaluated and seek permission from EU authorities to place them on the market.

EIHA

European Industrial Hemp Association members agreed last year to submit a joint novel foods application with “a range of CBD extracts” to UK and EU authorities. The group said in February it was receiving membership applications “on almost a daily basis” from interested parties.

This week, the EIHA confirmed a report that revealed the scope and costs associated with its joint novel foods application. The association told Hemp Industry Daily:

  • An EIHA task force is in the process of choosing four formulations of CBD to be consolidated into one novel food application. The formulations will be finalized at the EIHA general meeting in June.
  • The joint application project, organized as a limited liability company, will cost at least €2 million ($2.16 million). The EIHA estimates that the required lab analysis of CBD and THC toxicology studies alone will cost €1.8 million ($1.94 million).
  • The group plans to launch the toxicology studies in June.
  • The cost of joining the consortium is estimated at €10,000 to €50,000 ($10,800 to $54,000), depending on the size of the company and when it joins. Regular EIHA members will be asked to pay the consortium cost in two installments, with the first next month.
  • This one-time cost comes in addition to the cost of a regular EIHA membership, which ranges from €2,500 to €10,000 ($2,700 to $10,800), depending on company revenue.
  • All companies that join the EIHA are obliged to join the novel foods consortium.

The association declined to say how much of the necessary funding for lab tests and toxicology evaluations has been raised so far.

Lorenza Romanese, managing director at the EIHA, said companies outside the European Union can join its novel foods consortium and would be eligible to sell products on the EU market if the joint application achieves authorization.

ACI

The UK’s Association for the Cannabinoid Industry announced this week a free hotline for CBD manufacturers with questions about the novel food application process.

The group also offers paid consulting services for individual applications.

The ACI’s approach pools resources for the data-generation phase while taking an individualized approach for each company’s application. The effort aims to help companies get the research they need, said Shomi Malik, ACI’s development director.

“The most expensive part of this isn’t writing the dossier, it’s generating the data,” Malik said.

“The best of both worlds is to share the costs of the real heavy lifting but still give companies the freedom to do their own individual applications. That’s what we’re trying to do here.”

The ACI estimates that the cost for the toxicology study alone – the portion it’s looking to syndicate – will cost around £250,000 ($309,000). A full toxicology assessment takes seven to eight months to complete, ACI said, followed by an extra month to generate the data report.

The group said its application consulting services could cost anywhere from €50,000 to €500,000 ($54,000 to $540,000), depending on the size of the company and the number of finished products requiring novel foods authorization.

Malik applauded the EIHA for its collective application option, which he said might appeal to CBD players who haven’t budgeted the financial resources required for an individual application.

“Now that ‘novel foods’ is a binary proposition – you’re either in or you’re out – companies have had to find budgets from somewhere,” he said. “Their objective is to do this the quickest and cheapest way possible.”

On the other hand, in the event that a collective novel foods application is authorized, parties to the application run the risk of finding themselves in a “regulatory straitjacket” not to deviate from those formulations. This could hinder industry innovation, Malik said.

“You’re in a much better position if you’ve got your own novel food authorization, than if you have to share and compromise with some aspects on the data sharing,” Malik said.

Clock is ticking

Whichever path companies choose, it’s time to start the process for any products they want to keep on the shelves next year, said Garrett Graff, an attorney at Hoban Law Group who advises companies doing business in Europe and the UK.

“It’s important that folks get started now,” Graff told Hemp Industry Daily.

“This is not a commonplace application that takes a couple hours. This will take considerable amounts of planning, coordination, time and financial resources to complete, and engaging as quickly as possible given the forthcoming deadline is important.”

SOURCE: https://hempindustrydaily.com/hemp-groups-pool-resources-to-ensure-path-to-cbd-market-in-europe/

Mota Ventures $MOTA.ca Acquires A Record 17,996 New Customers in April $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 11:05 AM on Tuesday, May 5th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / ACCESSWIRE / May 5, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC PINK:PEMTF) (the “Company“) is excited to announce for the month of April, it acquired 17,996 new customers. This represents an increase of 48% compared to April 2019. In April, the Company also experienced strong demand from customers enrolling in a subscription, totaling of 14,091 new subscribers during the month. This represents a new subscriber increase of 78% compared to April 2019.

The Company’s Natures Exclusive brand offers a CBD hemp-oil formulation intended to provide users with the therapeutic benefits that hemp may offer. The hemp oil used in the products is derived from hemp grown and cultivated in the United States. The extraction process is designed to maintain all the beneficial qualities that hemp may offer. Natures Exclusive offers a range of products, which include CBD oil drops, CBD gummies, CBD pain relief cream, CDB skin serum and CBD coffee.

“We continue to see strong consumer demand for our entire range due to our concentrated customer acquisition efforts and by providing compelling products our customers are asking for. Our April new customer acquisition and subscription numbers are continued evidence of the strength of the business. Additionally, I am excited about our recent launch of a CBD hand sanitizer product and anticipate we will see very strong sales through this current quarter,” stated Ryan Hoggan, CEO of the Company.

The Company also announces that it has granted 7,995,000 incentive stock options to certain directors, officers and consultants of the Company. The options vest immediately, and are exercisable at a price of $0.30 for a period of 60 months. The options are governed by the terms of the Company’s incentive stock option plan, and the policies of the Canadian Securities Exchange.

About Mota Ventures Corp.

Mota Ventures is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the Company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan

Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Discovering the Benefits of CBD Oil SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 2:25 PM on Wednesday, April 29th, 2020

SPONSOR: Mota is seeking to become a vertically integrated global CBD brand. Mota is creating sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota. Combined total sales of almost $29,000,000 with a EBITDA of approximately 12.5% (2019) . Click Here for More Info

Mota large

CBD oil is increasingly acclaimed for its benefits. Use as an e-liquid for vaping, but also as a dietary supplement to fight against stress or depression, CBD is everywhere.

Find out what its benefits are, how to consume it, and where to find it.

With some of the best online suppliers in Europe, British users can now easily find and order CBD flowers in UK. It has simplified the way to purchase high-quality CBD online, and we can now enjoy the best CBD oils.

What is CBD oil?

CBD, or cannabidiol, is part of the family of cannabinoids, a group of molecules found in the hemp plant, such as THC or CBD. We all have so-called cannabinoid receptors in our brains, which explains why these compounds have a more or less significant impact on the human nervous system.

CBD oil is extracted from the cannabis plant. It contains mostly cannabidiol, the concentration of which varies depending on the product. Today it is mainly used as an e-liquid for electronic cigarettes, as CBD oil to add in food and drinks, and CBD capsules.

While the hemp plant has been cultivated for over 6.000 years in China, it is only today that CBD oil is becoming more and more popular, as scientists discover many benefits for our organism. Indeed, unlike THC, another cannabinoid, CBD does not have psychotropic properties. For this reason, cannabidiol is also called “therapeutic cannabis”!

What are the effects of CBD oil?

Unlike THC, the effects of CBD oil are not harmful to our nervous system. CBD does not cause a feeling of intoxication or euphoria, unlike THC, and therefore no loss of control.

Conversely, it offers a feeling of serenity and a sense of relaxation. CBD is also found in recognized drugs like Cannador, Sativex, or Epidiolex.

To start with, CBD oil can help you fall asleep. If it does not have the effect of a sleeping pill, it will, however, cause your body to relax to promote falling asleep indirectly.

Likewise, CBD oil can help you not only to combat stress but also to regulate your mood. Indeed, CBD acts in particular on receptors linked to anxiety. For this reason, it is reputed to be a powerful anxiolytic and is effective in treating depression.

Note that paradoxically, CBD oil can help you fight against drug addiction since it will promote emotional balance while helping you overcome anxiety and stress, often overwhelming during withdrawal.

Finally, CBD oil can be used as an anti-inflammatory, especially in the case of Crohn’s disease, a chronic inflammatory disease of the digestive system.

How should you use CBD oil?

CBD oil is consumed orally, by placing 1 to 2 drops on your tongue or by adding them to your food or drink. The bottles sold are therefore often equipped with a pipette. After swallowing the CBD oil drops, leave it on for 30 seconds before continuing to eat or keep busy.

Please note, it is essential not to exceed 3 doses per day. If you take too much CBD oil, you risk increasing the relaxing effects and wanting to sleep! The ideal is to start with a low dosage and increase it gradually if you support it.

Also, CBD oil is not recommended for pregnant women.

Is CBD oil legal in the UK?

Cannabis derivatives do not have an outstanding reputation, in particular, because of THC, the compound which has psychotropic effects. European legislation is therefore relatively strict with cannabidiol. For example, any product containing THC is prohibited if the THC level exceeds 0.2 %.

However, products from Cannabis sativa seeds and stems are not prohibited in the UK, which explains why most of the CBD oils currently on sale come from them. Despite everything, CBD oil remains banned for minors. No law has been enacted regarding CBD oil, but case law prevails until European law issues an opinion on the subject, not always in a pleasant manner!

Where to buy CBD oil?

CBD-based products are very numerous: crystals (the purest form) for culinary preparations or other uses of this type, oil, e-liquid for electronic cigarettes, CBD flowers, CBD resins, etc. You will, therefore, have no harm to find CBD for your consumption.

On the Internet, you will mainly find CBD oil, as on the online store. You will find a whole lot of websites that are claiming to sell the best CBD products. However, you should only buy the best quality of CBD flowers and CBD oils.

Check websites such as Justbob.shop to find the right CBD products. As a leading company in Europe, this supplier from Italy is offering natural CBD flowers and great CBD oils. Also, they are following a set of many quality controls, and they are recognized by the Italian authorities, which means that they are well-known and that they are complying with local and European laws.

Source: London Loves Business

Mota Ventures $MOTA.ca Reports Interim Record of 14,388 New Nature’s Exclusive Customers for April. Success Supports Launch of CBD Hand Sanitizer $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 2:28 PM on Saturday, April 25th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / ACCESSWIRE / April 25, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company“) is pleased to announce an interim record number of new customer acquisitions for the month of April, for the period April 1st – 23rd. Specifically, a total of 14,388 new customers were acquired for the Nature’s Exclusive brand. This interim new customer acquisition record will be updated with the final results for the complete month of April.

In addition to the record customer acquisition number, the Company is pleased to report that each new customer spent an average of $US 151.96. Finally, the record number included 1,748 new customers that purchased products in the immune support category.

SUCCESSFUL ONLINE CUSTOMER ACQUISITION STRATEGY SUPPORTS LAUNCH OF CBD BASED HAND SANITIZER

The interim record results demonstrate the strength and ability of the Company’s online acquisition strategy to capitalize on the strong demand for natural health solutions. As a result, the Company will be launching a hand sanitizer product containing CBD through its Nature’s Exclusive brand on May 1, 2020. The Nature’s Exclusive CBD hand sanitizer will contain 70% ethyl alcohol as its active ingredient, as well as, CBD isolate and Vitamin E, and will initially be offered only to consumers in the United States.

In order to differentiate the Company’s hand sanitizer offering within this crowded space, Mota has formulated a product that is specifically designed for its target consumers by combining the antimicrobial properties of ethyl alcohol with the benefits of CBD. This ability to formulate and innovate new products of this caliber is a direct result of the Company’s strong supply chain, which has continued to operate uninterrupted despite the recent worldwide turmoil.

“I am very pleased with the continued strength of our new customer acquisition month-to-date as demand remains strong for our CBD and immune products. We anticipate similar demand for our new CBD Hand Sanitizer product due to the limited availability of sanitizer through current retail and eCommerce channels. This product offering will allow us to reach a new client base, while generating significant gross margin and attracting clients to our other product lines” stated Ryan Hoggan, CEO of the Company.

The Company will be hosting an investor conference call at 2:15pm PST on Monday, April 27, 2020 with Mota Ventures management, Ryan Hoggan, CEO and Joel Shacker, President. The Company will be accepting questions from investors at the end of the call.

Conference details:

Canada/USA TF: 1-800-319-4610
International Toll: +1-604-638-5340
Germany TF: 0800-180-1954
Callers should dial in 5 – 10 min prior to the scheduled start time and simply ask to join the call.

Conference replay

Canada/USA TF: 1-800-319-6413
International Toll: +1-604-638-9010
Replay Access Code: 4481

This News Release is available on the company’s CEO Verified Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact the President of the Company, Joel Shacker, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Mota Ventures $MOTA.ca Announces DTC Eligibility for Common Shares $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 9:32 AM on Thursday, April 23rd, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / April 23, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTCPINK:PEMTF) (the “Company“) is pleased to announce that it has received approval from the Depository Trust Company (“DTC“) to make the Company’s common shares eligible to be electronically cleared and settled through DTC (“DTC Eligibility“).

DTC is a subsidiary of the Depository Trust and Clearing Corporation, a United States company that manages the electronic clearing and settlement of publicly traded companies. DTC Eligibility incorporates an electronic method of clearing securities that speeds up the receipt of stock and cash, and thus accelerates the settlement process for certain investors. DTC is a member of the U.S. Federal Reserve System, a limited-purpose trust company under New York State banking law and a registered clearing agency with the U.S. Securities and Exchange Commission.

In addition to trading over-the-counter in the United States under the ticker symbol “PEMTF”, the Company’s common shares continue to trade on the Canadian Securities Exchange under the symbol “MOTA” and on the Frankfurt Stock Exchange under the symbol “1WZ”.

“We are very pleased to have obtained DTC eligibility as it simplifies the process of investors and brokers trading and exchanging our stock in the United States, which will benefit Mota and our shareholders. I also expect that being DTC eligible will improve our overall liquidity and help to broaden our shareholder base in North America,” stated Ryan Hoggan, CEO of the Company.

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the Company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brands. Within Europe, its Satavida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Mota Ventures $MOTA.ca Raises $2.8 Million in Additional Private Placement $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 8:03 AM on Wednesday, April 22nd, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / ACCESSWIRE / April 22, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTCPINK:PEMTF) (the “Company“) is pleased to announce that it has completed a further offering (the “Offering“) of 9,944,000 units (each, a “Unit“) by way of non-brokered private placement at a price of $0.28 per Unit for gross proceeds of $2,784,320. Each Unit consists of one common share of the Company, and one common share purchase warrant (each, a “Warrant“) exercisable to acquire an additional share at a price of $0.38 for a period of twenty-four months, expiring on April 21, 2022. When combined with the earlier offering completed by the Company on April 1, 2020, the Company has raised gross proceeds of $4,504,320.

The Company anticipates utilizing the proceeds of the Offering to further develop and market products in North America and Europe using its ecommerce sales channels, to satisfy compensation obligations owing to employees based on services provided to the Company and the satisfaction of performance metrics and for general working capital purposes. In connection with completion of the Offering, the Company has paid $75,120 and issued 262,857 common shares and 268,287 Warrants to certain arms-length parties who assisted in facilitating the Offering. The Company has also issued 142,857 Warrants to an arms-length consultant, as partial consideration for services provided to the Company.

All securities issued in connection with the Offering are subject to a four-month-and-one-day statutory hold period in accordance with applicable securities law.

About Mota Ventures Corp.

Mota Ventures is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value-added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year-round growing conditions and access to all necessary infrastructure. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Joel Shacker
President

For further information, readers are encouraged to contact Joel Shacker, President, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

CBD In Medicine: Relief and Regulation SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 11:40 AM on Tuesday, April 21st, 2020
  • Neuropharmacologist and Functional Medicine practitioner Dr Elisabeth Philipps tells MCN about the therapeutic benefits of CBD and talks about CBD regulation.

MCN speaks to Dr Philipps about the science behind the health benefits of CBD and the need for standardised regulation of CBD food supplements.

Dr Elisabeth Philipps is a neuropharmacologist and practitioner in Functional Medicine with over 18 years’ experience. She operates a thriving health consultancy in the UK specialising in CBD, brain and gut health; where she provides expert opinion for private clients, corporate business programmes, the national media, specialist healthcare publications and health companies.

How did you first become aware of the endocannabinoid system and the therapeutic benefits of cannabis?

I’m a neuropharmacologist by training, so I’ve been aware of the medicinal therapeutic benefits of cannabis for a number of years. The endocannabinoid system was only discovered in the 1990s so it’s actually a relatively recent system that we’ve known about in the body, but it’s only been in the last two to three years that my focus has become much more intense on the endocannabinoid system, medicinal cannabis and CBD oil supplements; because of the rise in profile of those products.

What are the potential dietary benefits of consuming CBD or hemp?

The two products are quite different: hemp is extract of the whole plant, so the dietary benefits of hemp normally come from the hemp seed – you could have the seeds ground or sprinkled on top of your food, for example; maybe hemp seed oil which makes a good salad dressing. Hemp oil extracts are rich in very beneficial omega-3 and omega-6 essential fatty acids; you also find things like protein and fibre as well as minerals and vitamins: magnesium and phosphorus, for example, are found within the hemp seeds themselves.

CBD is an even more refined extract from the hemp plant flowers rather than the seeds, so there’s not so much [in the way of] dietary benefit; but it contains the compounds such as the phytocannabinoids, and other compounds such as flavonoids and terpenes, which can confer health benefits; so you get the dietary benefits from hemp seeds and hemp seed oil and you get other health benefits from consuming CBD.

What kind of conditions and ailments do you find that people are using CBD for?

[There are] three primary areas that people find CBD works for them: the sleep area, to help improve the quality of sleep; people report being able to [get to] sleep more easily, stay asleep and feel more refreshed when they wake up. [The second area is] pain, which comes in many different forms – it can be nerve pain or neurogenic pain or inflammatory pain, so conditions such as arthritis, for example, or more acute conditions such as sporting injuries or general inflammatory injuries. People report taking CBD oil as helping to reduce the response to pain. What’s been very interesting in the study of CBD and phytocannabinoids in pain pathways is that not only is it blocking the pain pathways themselves in the spinal cord and brain, but also CBD acts within the parts of the brain that helps change our perception of pain. That’s really key, because it’s how we respond to the pain signals in our bodies that gives us the intensity of the experience; so CBD is an important component of a programme to help manage different types of pain.

The third area that I find CBD can really help is in mood, in particular [for patients who are] feeling anxious or stressed. CBD has this ability, through various pathways in the brain, to help balance the systems that help us feel better, to improve wellbeing, to improve our mood. CBD works at the neurotransmitter level, transmitting chemicals in the brain that send signals to help provide a balance. There are a number of studies coming in: they’re relatively small scale, but they’re looking at CBD oil for anxiety and for sleep and they have showed improvement in those areas; but the science is beginning to play catch-up now as well.

What is the science behind the effects of CBD on different symptoms?

CBD interacts with our own endocannabinoid system and I think that’s really key, because when you take a medicine it’s a very blunt tool: it either turns something on or turns something off; it blocks a response or it produces a response. CBD is lot more subtle than that within the body, because it works within the endocannabinoid system and that system is spread throughout our body – the endocannabinoid system is in the gut, the brain, in the immune cells, in the lungs, in the skin – so that’s why CBD can have such a diverse number of effects.

We produce our own cannabinoids within the body to stimulate and produce effects; and CBD helps balance the body’s production and the body’s ability to activate the endocannabinoid system through its own naturally produced mediators. There’s a lot of science showing how CBD acts within the endocannabinoid system and produces its responses.

What advice do you have for consumers when choosing a brand or product to ensure it is good quality and does not contain any unlisted ingredients?

This can be a very confusing area, because there are so many products that have hit the market. First of all, a CBD food supplement is legal in the UK if it contains less than 0.2% THC or tetrahydrocannabinol. That is the cannabinoid which causes the commonly associated high or buzz that you get from marijuana; it’s only present in hemp in very low levels anyway and it’s been stripped out of CBD oil. You need to ensure that you’re taking a legal product that contains less than 0.2% THC; and you can do that by asking the company for a certificate of analysis.

Every batch of CBD oil that a reputable company receives will have had a third-party laboratory testing [conducted] on that particular batch of oil, which will have a batch number so it can all be traced. That will show the breakdown of the different cannabinoids and the different constituents of that particular oil so you’ll be able to see not only that it contains the legal limit or less of THC, but the amount of CBD that it says on the label as well – that’s where the product can vary drastically, so you need to have a look at that certificate of analysis to show that it contains the CBD that you want. You will find some companies selling 0% THC products, which are very useful especially if you are drug tested for work or if you’re a professional athlete. The Banned Substances Control Group (BSCG) can test for THC and other banned substances and can provide a certificate to show that you don’t have any of those substances within your product. Reputable companies should have their certificates of analysis on their websites; or have a chat with them and they should provide that information for you.

How do you anticipate the market will evolve in over the next few years?

This is a very interesting time for CBD and medical cannabis: there’s obviously a lot going on and there’s a lot in the news. I think there needs to be more CBD regulation within the industry, because there’s a wide range of products on the market that differ in terms of their CBD content and what they purport to have in them; so there needs to be more CBD regulation, there’s no doubt about that. Equally [there is a question of] how that CBD regulation is brought in: the industry is playing catch-up in a way because the popularity of the product has grown exponentially in the last few years.

What we need to see is regulation, working with food standards agencies and [other regulators] at a government level. I think that will evolve over the next few months and years; and it’s going to be [because of] FourFive and other reputable companies that are working with the regulators, to help the industry in a way that protects it and still provides consumers with quality products.

Working on the assumption that further CBD regulation is likely to be introduced, do you expect this to impact patients using these products?

There is no doubt that the CBD regulation will change; and that it needs to protect the industry in terms of protection of products and protect consumers as well. I think it’s a case of companies and experts working with both agencies and the regulators: the impact on patients is our primary concern; and we are working towards avoiding any impact so there is seamless availability of quality products on the market. That is a goal that everyone is working to at the moment: every country is different and we’re just going to have to keep working together to make sure that high quality products [are going] to be readily available.

Do you anticipate Brexit having an impact, either positive or negative, on CBD regulation and medicinal cannabis regulation?

Brexit will potentially free up time and space for this topic to be higher up agendas. I believe that Brexit has possibly moved discussions of CBD and medical cannabis off the table or further down the list [of priorities]. I do think we’ll see more discussions happening in the next few weeks and months as Brexit resolves. At the moment we’re still working under European guidelines, in terms of the food supplement side at least, but it will be interesting to see how that pans out as we leave Europe; and as with many different areas of Brexit it’s still a bit of an unknown as to how EFTA’s [the European Free Trade Association] regulations and rules will affect the Food Standards Agency on the UK side. There will definitely be more discussion around this, certainly in the groups that I’m involved with; and we know that there are greater discussions to be had in the next few months.

Dr Elisabeth Philipps
Nutritional Therapist
www.hartwellnutrition.co.uk

SOURCE: https://www.healtheuropa.eu/cbd-in-medicine-relief-and-regulation/99418/

MOTA Ventures $MOTA.ca Generates $4.29 Million in Revenue During March 2020 $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 9:23 AM on Monday, April 20th, 2020
Mota large
  • Generated CAN$4,290,000 with related expenses of $4,240,000
  • The Immune Support product line experienced further positive growth contributing to First Class acquiring 20,959 new customers during the month of March

VANCOUVER, BC / ACCESSWIRE / April 18, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTCPINK:PEMTF) (the “Company“) is excited to announce that for the month of March 2020, its First Class CBD brand achieved sales of Cdn$4,290,000, with related expenses of Cdn$4,240,000. Customer acquisition expenses for March 2020 include one-time costs of approximately Cdn$1,160,000 associated with the introduction of the new line of Immune Support and CBD products. The Immune Support product line experienced further positive growth contributing to First Class acquiring 20,959 new customers during the month of March. The all-natural Immunity Blend is made from 100% pure essential oils, including cinnamon leaf, lemon, clove bud, lime, eucalyptus globulus, rosemary, peppermint, spearmint and oregano. The Company also launched an Immune CBD oil, along with an Elderberry Gummy product. The new Immune CBD product contains CBD, B3, B12, Vitamin C and Zinc. Sales for March 2020 compare to sales of Cdn$1,280,000 during the same period last year, representing an increase of 235%.

The Company also introduced a new brand, Nature’s Exclusive CBD, in the first week of April 2020. The Nature’s Exclusive CBD brand will offer a range of products, which include the new Immune CBD oil, Elderberry gummies, CBD oil drops, CBD gummies, CBD pain relief cream, CBD skin serum and CBD coffee.

First Class offers a CBD hemp-oil formulation intended to provide users with therapeutic benefits that hemp may offer. The hemp oil used in the products is derived from hemp grown and cultivated in the United States. The extraction process is designed to maintain all the beneficial qualities that hemp may offer. First Class offers a range of products, which include CBD oil drops, CBD gummies, CBD pain relief cream, CBD skin serum and CBD coffee. First Class plans to continue its significant growth in their U.S. operations over the balance of 2020, as well as an expansion into the European market.

“I am extremely pleased with the performance of our business during March 2020, a month where the world and the economy faced immeasurable challenges. Our ability to efficiently innovate and launch new products, is a perfect example of our primary competitive advantage, and what allows us to be a leader in the ecommerce space. We expect our investment in accelerated customer acquisition from February to March, including a one-time cost of Cdn$1,160,000, will continue to produce significant revenue growth, and are hopeful it will lead to increased profitability in the upcoming months,” stated Ryan Hoggan, CEO of the Company.

The Company cautions that figures for revenue, expenses and margin generated from the sale of First Class CBD products have not been audited, and are based on calculations prepared by management. Actual results may differ from those reported in this release once these figures have been audited. These figures were translated from US dollars into Canadian dollars using the Bank of Canada monthly average exchange rate of US$1.00:Cdn$1.3953 for March 2020 and US$1.00:Cdn$1.3368 for March 2019.

About Mota Ventures Corp.

Mota is an established ecommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the Company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature’s Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com